VBI Vaccines (NASDAQ:VBIV) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Friday, March 2nd.
According to Zacks, “VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus vaccine. Its second platform is a thermostable technology that enables the development of vaccines and biologics. VBI Vaccines Inc., formerly known as SciVac Therapeutics, Inc., is headquartered in Cambridge, MA. “
A number of other equities analysts have also recently issued reports on the stock. BMO Capital Markets started coverage on shares of VBI Vaccines in a research report on Wednesday, November 15th. They issued an “outperform” rating and a $11.00 price objective on the stock. BidaskClub cut shares of VBI Vaccines from a “hold” rating to a “sell” rating in a research report on Saturday, January 20th. Three analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $8.75.
In related news, CEO Jeff Baxter bought 10,000 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were purchased at an average price of $3.89 per share, with a total value of $38,900.00. Following the purchase, the chief executive officer now owns 140,646 shares of the company’s stock, valued at approximately $547,112.94. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 54.50% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. boosted its stake in shares of VBI Vaccines by 36.0% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 58,200 shares of the biopharmaceutical company’s stock valued at $249,000 after purchasing an additional 15,400 shares in the last quarter. TIAA CREF Investment Management LLC boosted its stake in VBI Vaccines by 24.8% during the fourth quarter. TIAA CREF Investment Management LLC now owns 78,369 shares of the biopharmaceutical company’s stock worth $335,000 after acquiring an additional 15,557 shares in the last quarter. California State Teachers Retirement System boosted its stake in VBI Vaccines by 52.5% during the fourth quarter. California State Teachers Retirement System now owns 54,460 shares of the biopharmaceutical company’s stock worth $233,000 after acquiring an additional 18,760 shares in the last quarter. Kamunting Street Capital Management L.P. boosted its stake in VBI Vaccines by 64.4% during the fourth quarter. Kamunting Street Capital Management L.P. now owns 49,308 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 19,308 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in VBI Vaccines by 54.2% during the fourth quarter. Bank of New York Mellon Corp now owns 68,478 shares of the biopharmaceutical company’s stock worth $293,000 after acquiring an additional 24,072 shares in the last quarter. 48.64% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “VBI Vaccines (VBIV) Downgraded to Sell at Zacks Investment Research” was first reported by Week Herald and is owned by of Week Herald. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://weekherald.com/2018/03/10/zacks-investment-research-lowers-vbi-vaccines-vbiv-to-sell.html.
VBI Vaccines Company Profile
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.